>Go!

We Live Open Science

A Different R&D Path that Defines the Company’s Position

The ecosystem delivering biopharmaceutical innovation has shifted. Where global pharma companies had previously discovered, developed and delivered new products from their own labs, now the driving source of innovation is coming from smaller biotechnology and specialty pharma companies, as well as academia. 

Given this shift in innovation origination, Allergan has sought to follow a different R&D path than other companies. We embrace an Open Science model. It defines the Company’s position in this new ecosystem – as a magnet for game-changing ideas and innovation. A large percentage of our pipeline is sourced by partnering with biotech companies, academia and other pharmaceutical companies globally. Through this Open Science model, we drive strong R&D productivity by delivering innovative therapies that create long-term shared value for Allergan, for customers and for patients.

Strong Productivity in 2015

Open Science has helped to build leadership in several therapeutic areas and drive the Company's long-term growth. The Company's R&D pipeline delivered strong productivity in 2015, with more than 20 major pharma and device submissions and more than 25 major pharma and device approvals.  Through this Open Science strategy, during the last year the Company has added multiple late-stage product opportunities from the innovation ecosystem across our key therapeutic areas, including from the recent acquisitions of Kythera, Naurex, Oculeve, AqueSys, Topokine and a licensing agreement with Merck to acquire the rights to its oral CGRP compounds. 

All programs enter into our best-in-class product development and commercialization organization to build a sustainable development portfolio that addresses unmet needs and aligns with our key therapeutic areas

More than 65 Programs in Development 

Today, Allergan has more than 65 programs in development across our seven therapeutic areas, with key candidates for global development in Medical Aesthetics and Dermatology, Eye Care, Central Nervous System disorders, Gastroenterology, Women’s Health, Urology and Anti-infectives. 

Allergan is committed to this strategy, and to continuing to invest significant dollars in R&D annually.